KalVista Pharmaceuticals to Present Data at the 2022 American College of Allergy, Asthma & Immunology

October 27, 2022

KalVista today announced the acceptance of multiple abstracts at the 2022 Annual Scientific Meeting for the American College of Allergy, Asthma & Immunology.

KalVista Pharmaceuticals (NASDAQ:KALV)

CAMBRIDGE, MA, USA, October 27, 2022 /EINPresswire.com/ -- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2022 Annual Scientific Meeting for the American College of Allergy, Asthma & Immunology taking place in Louisville, Kentucky from November 10-14. The presentations are:

- Impact of Hereditary Angioedema (HAE) Attacks on Quality of Life and Activities of Daily Living: Paula J. Busse, Teresa Caballero, Sally van Kooten, Sherry Danese, Ledia Goga. Results shared as a poster presentation and Q&A on Friday, November 11 from 3:15-3:30 p.m. ET at Monitor 10, Upper Concourse of the Exhibit Hall
- Real-World Treatment Burden Associated with Parenteral On-Demand Therapies for Hereditary Angioedema: Raffi Tachdjian, Sinisa Savic, Moshe Fridman, Joao Frade, Paul K. Audhya, Marie Fasehun. Results shared as a poster presentation and Q&A on Friday, November 11 from 3:30 to 3:45 p.m. ET at Monitor 9, Upper Concourse of the Exhibit Hall

About KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors for diseases with significant unmet need. KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME). KalVista is developing sebetralstat as an oral on-demand therapy for HAE attacks and is enrolling the Phase 3 KONFIDENT clinical trial. In addition, KalVista’s oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve treatment for people living with HAE. In DME, an intravitreally administered plasma kallikrein inhibitor, called KVD001, has completed a Phase 2 clinical trial.

For more information about KalVista, please visit www.kalvista.com.

For more information on the sebetralstat HAE on-demand Phase 3 KONFIDENT trial, please visit www.konfidentstudy.com.

Forward-Looking Statements

This press release contains “forward-looking” statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. These statements are subject to numerous risks and uncertainties, including the potential impact of COVID-19, that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, timing or outcomes of communications with the FDA, our expectations about safety and efficacy of our product candidates and timing of clinical trials and its results, our ability to commence clinical studies or complete ongoing clinical studies, including our Phase 3 KONFIDENT trial, and to obtain regulatory approvals for sebetralstat and other candidates in development, the ability of sebetralstat and other candidates in development to treat HAE or DME, and the future progress and potential success of our oral Factor XIIa program. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2022, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Jarrod Aldom
KalVista Pharmaceuticals
+1 201-705-0254